Abstract 90P
Background
Colorectal cancer (CRC) is a major worldwide health problem due to its high prevalence and mortality rate. MicroRNA has been reported playing an important role in a variety of cancers including colorectal cancer.
Methods
CRC tissues as well as CRC cell lineswere used to evalute the expression and function of miR-133a-3p, SP1 and IGF1R. The relationship between miR-133a-3p and clinical-pathological charateristics of CRC patients were analyzed. The interaction among miR-133a-3p/SP1/IGF1R was assessed using Dual Luciferase reporter.
Results
MiR-133a-3p has been found down-regulated in CRC tissues compared with the adjacent normal tissues. The expression of miR-133a-3p was significantly associated with histological differentiation (P=0.01) and TNM stage (P=0.006) respectively. CRC patients with low miR-133a-3p expression had a significantly shorter survival time than those patients with high miR-133a-3p expression (P=0.04). Gain-of-function assays showed that miR-133a-3p inhibited cellular proliferation and colony formation, but had no effect on migration and invasion of CRC cells. Furthermore, expression of SP1 and IGF1R was reduced by elevating miR-133a-3p expression in CRC cells. Luciferase assay further confirmed that SP1 but not IGF1R was the target gene of miR-133-3p and SP1 could bind to the promoter region of IGF1R gene.
Conclusions
In summary, our findings first demonstrate that miR-133a-3p acts as a tumor suppressor by targeting SP1 and miR-133a-3p/SP1/IGF1R signaling pathway is involved in CRC progression. MiR-133a-3p may be a novel molecular therapeutic target for CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session